Key takeaways
- Claims about MOTS-c fall into three areas, metabolism, exercise capacity and ageing, and the studies that gave it were in mice and cells.
- The mouse studies, from the group that described MOTS-c, measured weight gain and insulin response on a high-fat diet (2015) and treadmill running at three ages (2021).
- In old mice, the lifespan result was only a trend, and the authors wrote that larger cohorts are needed.
- Human studies so far measured natural MOTS-c levels, after exercise or across ages; none gave MOTS-c, and a phase 2a trial is recruiting.
- FDA staff called the clinical relevance of the animal findings “currently unknown” and the safety risks in people unknown; WADA prohibits MOTS-c at all times.
01MOTS-c claims at a glance: model, sample, tier
Each claim, the main study behind it, and what that study cannot tell you. Dated 18 November 2026; sources at the end of the page.
| Area and what was measured | Study | Model and n | Tier | Not known |
|---|---|---|---|---|
| Metabolism: insulin response, body weight | Lee et al., 2015 | Cells; male mice on a high-fat diet, 10 per group | T4, T3 | Any effect in people; one trial is recruiting |
| Exercise: treadmill running | Reynolds et al., 2021 | Mice aged 2, 12 and 22 months, 5 to 19 per group | T3 | Any effect on performance in people |
| Exercise and natural levels | Reynolds et al., 2021; von Walden et al., 2021 | 10 young men; 30 adults randomised to exercise or none | T2 (natural levels) | Whether a rise matters, or what giving MOTS-c does |
| Ageing: grip, gait, walking, lifespan | Reynolds et al., 2021 | Old male mice started at 23.5 months, 18 treated and 19 controls; 5 to 12 per group in the late-life tests | T3 | Lifespan: a trend only; nothing in people |
| Ageing: natural levels and genes | D’Souza et al., 2020; Fuku et al., 2015 | Healthy men, 26 per age group; a gene-variant hypothesis | T2 (association) | Cause and effect |
02What did metabolism studies of MOTS-c measure, and in which models?
Cells and mice, 2015 (T4, T3). The paper that described MOTS-c, a 16-amino-acid peptide encoded in mitochondrial DNA, proposed from cell experiments that it acts on the folate cycle and activates AMPK, an enzyme that senses a cell’s energy state, and that skeletal muscle “appears to be” its main target. In male mice on a high-fat diet (N=10 in the paper), the authors reported less weight gain and lower insulin levels than in untreated mice on the same diet, with the same calorie intake; in mice on a normal diet, it had no effect on body weight. In 12-month-old mice (N=6), they reported that muscle took up glucose in response to insulin at levels “comparable to young animals”. One author held shares in and consulted for CohBar, Inc., and another consulted for it.
People: natural levels (T2). A 2018 case-control study in China measured blood MOTS-c in 40 children and adolescents with obesity and 57 controls. Levels were lower in the obesity group, a difference seen in boys but not in girls, and in boys they correlated with markers of insulin resistance. A correlation cannot show that low MOTS-c causes anything, or that giving it would change anything.
A registered trial that gives MOTS-c to people measures insulin sensitivity and has no results yet: see below. The basics of the peptide are in the MOTS-c guide.
03What did exercise studies of MOTS-c measure, and in which models?
Mice, 2021 (T3). The same research group reported better treadmill running in young (2 months), middle-aged (12 months) and old (22 months) mice given MOTS-c, in groups of 5 to 19. Two authors declared consulting roles and shares in CohBar, Inc.
People: natural levels (T2). In the same paper, 10 young men cycled, and MOTS-c rose in their muscle and blood. A 2021 Swedish study randomised 30 adults to endurance exercise, resistance exercise or no exercise (10 each): blood MOTS-c “showed a trend to increase” after endurance exercise, and blood levels were not related to fitness. Neither study gave MOTS-c to anyone.
Sport. WADA names MOTS-c in class S4.4.1, metabolic modulators, among activators of AMPK. It is prohibited at all times in the 2026 and 2027 Lists. See peptides and anti-doping and MOTS-c research.
04What did ageing studies of MOTS-c measure, and in which models?
Mice (T3). In the 2015 paper, MOTS-c levels in muscle and blood were lower in 32-month-old mice than in young ones (3 to 4 per group). In 2021, the group started old male mice on MOTS-c at 23.5 months (18 treated, 19 controls) and, after 30 months of age, reported better grip strength, stride length and 60-second walking results, measured in 5 to 12 mice per group. For lifespan, they reported only “a trend”, and wrote that “larger cohorts will be needed” to confirm it.
People: natural levels (T2). A 2020 study of healthy men aged 18 to 30, 45 to 55 and 70 to 81 (26 per group) found lower MOTS-c in the blood of older men, but about 1.5-fold higher levels in the muscle of middle-aged and older men than in young men. Two authors declared consulting roles and shares in CohBar, Inc.
Genes (T2, hypothesis). A 2015 letter described a variant in the MOTS-c coding region, m.1382A>C, found only in Northeast Asian populations, which the authors had earlier linked to reaching very old age in Japan. They proposed it “may be among” the mechanisms behind long lives in Japan, and wrote that “more research is needed”. More: longevity research.
05Has MOTS-c been tested in people, and what do regulators say?
No published study has given MOTS-c to people (PubMed and ClinicalTrials.gov, 18 November 2026): the five MOTS-c records PubMed indexes as clinical trials all measured natural levels. One trial is registered. NCT07505745 is a phase 2a, randomised, placebo-controlled trial planned for 120 adults with prediabetes and overweight or obesity, measuring an insulin-sensitivity index and adverse events. It began in February 2026 and is recruiting, with no results.
FDA. Reviewing MOTS-c in 2026, FDA staff found “a lack of evidence to evaluate the effectiveness” for the uses nominated. The studies were “limited to in-vitro and in-vivo rodent models”, had not tested how effects change with the amount given, and “the molecular target(s) through which MOTS-c acts remains unknown”, so “the clinical relevance” of the findings “is currently unknown”. They also cited a laboratory study in which MOTS-c is “quickly hydrolyzed in human blood”, which raises the question of whether it reaches active levels in people. On safety, they found no clinical studies or human exposure data, no FAERS reports through 9 March 2025 and no nonclinical toxicity studies, and concluded that “potential safety risks associated with the use of MOTS-c in humans are unknown”. FDA’s compounding page adds that MOTS-c products “may pose significant risk for immunogenicity for certain routes of administration”.
HHS. HHS’s 2026 policy appendix cites “a randomized placebo-controlled trial of a MOTS-c analogue” that “reported no serious adverse events”. It does not name the analogue or the trial, and an analogue is a different molecule. Status by country and the July 2026 committee vote: the MOTS-c guide.
06What we don’t know about MOTS-c
- Whether any mouse result applies to people. No completed human trial has tested one.
- Whether MOTS-c given from outside the body reaches active levels in people. FDA staff point to its rapid breakdown in human blood.
- Which molecule it acts on. FDA staff call its molecular target unknown.
- What natural MOTS-c levels mean. Level studies show associations, not cause and effect, and they point different ways: older men had lower blood levels but higher muscle levels.
- How independent the evidence is. The main mouse studies come from the group that described MOTS-c, and three of the papers cited here (2015, 2020, 2021) list authors with consulting roles and shares in CohBar, Inc.
How these tiers are assigned: evidence grades.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.